RSV severity markers in hospitalized adults
Part of Infections, Lungs & breathing clinical trials.
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be at least 18 years old
- Must have tested positive for RSV using a nose swab test
- Must be in the hospital (either in the ICU or a regular medical ward) due to breathing problems like cough, trouble breathing, or wheezing
- Cannot have another respiratory virus infection (like flu or COVID-19) at the same time
- You or a family member must say it's okay for you to join the study (no written consent needed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
This study tests an experimental RSV vaccine (IN006) in healthy adults to check its safety and how well it triggers an immune response. It may help protect against respiratory syncytial virus (RSV), which can cause serious lung infections.
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
This study looks at how common RSV (a virus that can cause serious breathing problems) is in older adults who are hospitalized with respiratory symptoms or worsening heart/lung conditions. By joining, you help researchers understand the virus and improve care for people your age.
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
This study looks at how RSV (a common virus that can affect breathing) leads to illness in young children who come to the doctor with ear infections and/or breathing symptoms. It may help doctors better understand the “burden” RSV causes in both home/outpatient and hospital settings.
Hear when a new Respiratory Syncytial Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.